MIST

News DTCC wins SEC nod for new SFT margin model; Wall Street eyes GS, MS, JPM balance sheets

20d ago

SEC filing MIST Reports $0.2M Revenue, $0.20 Loss per Share in Q1 2026

20d ago

Insider trade Sale by Joseph Oliveto (President and CEO)

39d ago

Insider trade Sale by Joseph Oliveto (President and CEO)

43d ago

SEC filing MIST Reports $200M Cash Runway to 2027, FDA Approves CARDAMYST Nasal Spray for PSVT, 2x Conversion vs Placebo, Launches in US Retail Pharmacies

74d ago

Insider trade Sale by Joseph Oliveto (President and CEO)

104d ago

Insider trade Sale by Amit Hasija (CFO & EVP of Corp. Development)

104d ago

Insider trade Sale by Jeffrey Edward Nelson (Chief Operating Officer)

104d ago

Insider trade Sale by Lorenz Muller (Chief Commercial Officer)

104d ago

Insider trade Sale by David Bharucha (Chief Medical Officer)

104d ago

News Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

153d ago

Scanner Unusual volume (z=8.6)

168d ago

Scanner Unusual volume (z=11.4)

169d ago

Scanner Unusual volume (z=11.4)

170d ago

News Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

171d ago

Scanner Unusual volume (z=11.4)

171d ago